To assess the potential of tumor-associated alternatively spliced gene products as a source of biomarkers in biological fluids, we have analyzed a large dataset of mass spectra derived from the plasma proteome of a mouse model of human pancreatic ductal adenocarcinoma. MS/MS spectra were interrogated for novel splice isoforms using a non-redundant database containing an exhaustive 3-frame translation of Ensembl transcripts and gene models from ECgene. This integrated analysis identified 420 distinct splice isoforms, of which 92 did not match any previously annotated mouse protein sequence. We chose seven of those novel variants for validation by reverse transcription polymerase chain reaction (RT-PCR). The results were concordant with the proteomic analysis. All seven novel peptides were successfully amplified in pancreas specimens from both wild-type and mutant mice. Isotopic labeling of cysteine-containing peptides from tumor-bearing mice and wild-type controls enabled relative quantification of the proteins. Differential expression between tumor-bearing and control mice was notable for peptides from novel variants of muscle pyruvate kinase, malate dehydrogenase 1, glyceraldehyde-3-phosphate dehydrogenase, proteoglycan 4, minichromosome maintenance, complex component 9, high mobility group box 2 and hepatocyte growth factor activator. Our results show that, in a mouse model for human pancreatic cancer, novel and differentially expressed alternative splice isoforms are detectable in plasma and may be a source of candidate biomarkers.
Introduction
Alternative splicing plays an important role in protein diversity without significantly increasing genome size. Aberrations in alternative splice variants contribute to a number of diseases including cancers (1, 2) . For example, Thorsen et al (2) identified cancerspecific splicing events in colon, bladder, and prostate tissues, with diagnostic and prognostic implications. The several alternatively spliced sequence databases now publicly available differ in their annotation and modeling methods and contain many transcripts not present in reference resources like Ensembl or Refseq (3) . The ECgene database is one of the largest alternatively spliced sequence databases (4) . Entries in this database are scored as high, medium, or low confidence reflecting the amount of cumulative evidence in support of the existence of a particular alternatively spliced sequence. Evidence is collected from clustering of ESTs, mRNA sequences and gene model predictions. We modified the ECgene database to include three-frame translations of the cDNA sequences (5) to determine the occurrence of novel splice variant proteins.
An important development in recent years is substantial improvement in tandem mass spectrometry instrumentation for proteomics, allowing in-depth analysis and confident identifications even for proteins coded by mRNA transcript sequences expressed at low levels (6) (7) (8) .
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal of human cancers due to absence of methods for early diagnosis and chemoresistance of advanced disease.
The Kras G12D /Ink4a/Arf mouse model of PDAC was engineered with signature mutations that recapitulate the histopathologic progression of the human disease in a highly reproducible and synchronous fashion (9, 10) . Here we exploit this model to test the hypothesis that cancer-specific alternative splice variants can be identified by in-depth mass spectrometric analysis of plasma proteins from this mouse model of pancreatic cancer. In this study, we have interrogated our modified ECgene database to identify both novel and known splice variants among circulating proteins. In addition, our analysis of quantitative expression ratios reveals variant proteins that are differentially expressed in pancreatic cancer.
Materials and Methods

Mass spectrometry data
Our search for alternative spliced forms used data from extensive proteomic analysis of plasma from 7 weeks old male wild type mice and KRas G12D /Ink4a-Arf mouse model of PDAC (10) . Approximately 1/3 of the Kras Ink4a/Arf mice present with the most common pathology observed in human cases -glandular. Plasma from Kras Ink4a/Arf mice with exclusively glandular tumor areas were used in this study. The samples were processed by Intact Protein Fractionation and Analysis System (11) protocol which incorporates immunodepletion to eliminate the most abundant plasma proteins, thus removing 90% of the protein mass. Immunodepletion was followed by isotopic labeling of protein cysteine residues with acrylamide, heavy (D3) for mutant and light (D0) for wild type samples. The mass difference between a D3 labeled and a D0 labeled cysteine residue is 3.01884 daltons. Samples from wild type and PDAC bearing mice were then pooled and the intact proteins were fractionated into 12 anion exchange (AX) fractions followed by 13 or more reverse phase (RP) fractions for each AX fraction yielding a total of 163 fractions. Individual fractions were digested with trypsin and analyzed using a ThermoFinnigan LTQ-FT mass spectrometer. Mass spectra from the LTQ-FT experiment were acquired as RAW files. The mzXML files containing the spectral information were extracted from RAW files using ReAdW.exe program (http://tools.proteomecenter.org).
The mzXML files were then searched against a modified ECgene database (for alternate splice variant analysis) using X!Tandem (12) software.
Modified ECgene Database
Alternative splicing can generate multiple transcripts from the same gene which are translated to splice isoforms (also known as splice variant proteins). Our target alternative splice variant protein database, the modified ECgene database, was constructed by combining Ensembl 40 and ECgene database (mm8, build 1). Taking alternative splicing events into specific consideration, ECgene combines genome-based EST clustering and the transcript assembly procedure to construct gene models that encompass all alternative splicing events. The reliability of each isoform is assessed from the nature of cluster members and from the minimum number of clones required to reconstruct all exons in the transcript (13 Ensembl transcripts were preferentially recorded over those generated from ECgene records. A collection of common protein contaminant sequences was added to this set.
Lastly, all sequences were reversed and appended to the set of forward sequences as an internal control for false identifications. This last step resulted in doubling the total number of entries in the modified ECgene database with a final total of 10,381,156 protein sequences.
Post search analyses
Trans Proteomic Pipeline (TPP)
For statistical purposes, the X!Tandem search results were post processed with PeptideProphet and ProteinProphet software using TPP (version 3.2) (http://tools.proteomecenter.org). First, we analyzed search results from each fraction separately using PeptideProphet, and then processed all PeptideProphet files together using ProteinProphet. Relative quantification of isotopically labeled peptides was performed using the Q3Ratio (14) and XPRESS (15) applications in TPP. The relative abundance of a peptide can be calculated, by reconstructing the light and heavy elution profiles of the precursor ions and by determining the elution areas of each peak. From
Q3Ratio and XPRESS analyses, we obtained the average expression ratio (mutant/wildtype) for those peptides that were unique to the splice variant protein identified and had labeled cysteine residue.
Michigan Peptide to Protein Integration (MPPI)
In addition to the TPP analysis, we implemented a second analysis based on selecting all peptide identifications with X!Tandem expect score of <= 0.001. We applied an integration process to these peptide identifications which greatly reduced the set of proteins and retained all of the peptide identifications. The integration process was as follows:
1) A list of all peptide matches was created.
2) The peptide list was ordered by the number of spectra matching each peptide.
3) Peptide with largest number of matching spectra was selected.
4)
A list of all proteins containing this peptide was made.
5) The protein list was sorted by the number of spectra matching peptides derived from the protein.
6) The protein with the largest number of matching spectra and which was identified by largest number of distinct peptides was selected. When equal numbers of identifying spectra were present, Ensembl proteins were given preference because these transcripts have been independently reviewed and Ensembl identifiers can readily be linked to additional annotation.
7)
All peptides contained within this protein were removed from the peptide list.
8)
Steps 3-7 were repeated until no peptides remained in the peptide list.
Protein identifications based on a single peptide from this MPPI analysis were retained only if identified by at least ten distinct spectra. For further analyses we used the union of protein identifications from TPP analysis with ProteinProphet probability > 0.9 and the MPPI. To remove redundant protein identifications, we ran another round of MPPI using all peptides found in either TPP or first phase MPPI (Figure 1 ).
Sequence analysis for novel proteins
The peptide sequences for which the alternative splice variant proteins were identified, were searched against the mouse genome (Build 37) using UCSC BLAT (16) browser and against NR using NCBI blastp (17) . In some cases, when the peptide sequences are short, the blat or blastp programs were not able to align correctly. 
Validation of the novel peptides by RT-PCRs
In order to corroborate the identifications of novel splice variants, peptide sequences with splice variations from seven novel variants were selected for validation by reverse transcription polymerase chain reaction (RT-PCR) ( Figure 4 ). We chose these seven peptide sequences as they were identified by multiple high scoring spectra (X!Tandem expect value < 0.001) (Supplementary Table 8 Table 8) were used in this method. PCR amplification was performed using the following profile:
1 cycle at 50°C for 30min, 1 cycle at 95°C for 10min, and 40 cycles at 94°C for 15s, 60°C for 1min. Calculations for relative quantification were performed as outlined in User Bulletin #2: ABI Prism 7700 Sequence Detection System (PE Applied Biosystems) (18).
Since we had access to only a single sample of pancreatic tissue from the wild type and mutant mice, respectively, we are unable to do biological sample replicates. However, we performed the quantitative RT-RCR three times using the same two samples to assess technical errors.
Functional annotation
The gene ontology (GO) annotation file for Mus musculus, was downloaded from http://www.geneontology.org/GO.current.annotations.shtml site and the GO terms associated with the parent gene symbols of the splice variants were studied. The functional annotations of the splice isoforms were done by searching the parent gene names using FuncAssociate (19) . FuncAssociate is a web-based tool that accepts as input a list of genes, and returns a list of GO attributes that are over -(or under-) represented among the genes in the input list. Only those over-(or under-) representations that are statistically significant, after correcting for multiple hypotheses testing, are reported.
Results
Summary of protein identifications
The mass spectra derived from plasma protein analysis were searched against the modified ECgene database using X!Tandem. The empirical false discovery rate (FDR) calculated based on peptide identifications from reverse protein sequences was < 0.5%
for all peptide identification scoring bins with X!tandem expect score < 0.001
(Supplementary Figure 1) . Protein and peptide identifications from the X!Tandem search and post-search TPP/MPPI analysis are summarized in Table 1 . Figure 1 summarizes the analysis workflow. TPP analysis of the search results yielded 1150 proteins with ProteinProphet probability >= 0.9 (FDR for proteins < 1.5%). In parallel, using our MPPI method (expect < 0.001), we identified a total of 1063 proteins (FDR for proteins < 1.5 %). There were 870 biological proteins identifications and 3 reverse sequences found in common by both approaches. Thus, the empirical FDR for proteins identified by both methods is <0.3%. The union of the TPP and MPPI methods resulted in 1340 protein identifications. There were 467 biological proteins and 22 reverse sequences identified by either TPP or MPPI but not by both. Thus, the empirical FDR for proteins identified by either but not both methods is <5%. The reverse sequence proteins identified by TPP and MPPI analyses were different; since we took the union of protein identifications from both methods, the false discovery rate at the protein identification level increased.
Taking the union of the two methods introduces some redundancy in identifications so we applied a second round of MPPI on these 1340 proteins yielding 1278 distinct protein identifications with 25 proteins from reverse sequence. Of the 1278 protein identifications, 420 were splice variant proteins (Supplementary Table 1 ).
Novel alternative splice variant protein identifications
To identify novel spliced sequences, we searched the peptide sequences of the 420 alternative splice proteins against the Mouse genome using blat and against NR database using blastp (see Methods); 92 of 420 alternative splice proteins were identified by unique peptides that did not align completely with any known mouse coding sequence (Figure1, Supplementary Table 2 ). These proteins are considered novel identifications.
Of these 92 identifications, 84 were novel alternative splice variants of known genes. An example is the identification of novel variant for peptidase inhibitor 16 (pi16) by the unique peptide 'ATEAPSSRETGAENPEK'. Figure 2 shows the alignment of this peptide to the known pi16 sequence by blastp. The alignment suggests a partial deletion (230 amino acids) of the exon sequence due to a splicing event resulting in the novel variant.
For 8 identifications from the 92 novel proteins, neither the complete protein sequence nor the peptides identified matched even partially to any known mouse proteins by blastp.
(parent gene name and gene symbol is given as null in Supplementary Table 2 ). However, we found that the complete protein sequences of these 8 proteins matched perfectly to various mouse genomic regions (Supplementary Table 3 ).
Both known and novel variant forms of many genes were found in the 420 protein set.
For example, we found seven variants of alpha-2-HS-glycoprotein including three known and four novel variant forms. A particularly interesting example is the identification of known and novel isoforms of muscle pyruvate kinase; the novel alternative splice variant, 'M9C5102_13_s4154_e5807_1_rf0_c1_n0| ', was identified by the unique peptide 'CLAAALIVLTESGR' from five different spectra. This peptide sequence did not align to the coding sequence of annotated mouse muscle pyruvate kinase protein. However, it aligned to human, rat and chicken muscle pyruvate kinase M1 isoform (Figure 3a) . The previously known mouse gene product for muscle pyruvate kinase (pkm2) gene, which is homologous to the M2 isoform of human and rat pkm2, was identified by 25 distinct peptides, 22 of which were shared by the novel mouse variant protein. Figure 3b shows identifications of unique peptides of a known isoform mouse malate dehydrogenase protein and its novel splice form from different clusters of reverse phase fractions; the isoform exhibits faster mobility by reversed phase chromatography.
Tumor related novel alternative splice variant proteins
By combining the Q3Ratio and XPRESS analyses, we calculated expression ratios for the cysteine containing unique peptides with splice variation from tumor bearing mice relative to controls for 28 of 92 novel splice variant proteins ( (20) (21) (22) . It is noteworthy that in our 92 novel proteins, we identified the presence of additional novel alternative splice variants of these proteins.
RT-PCR validations
The identifications of novel alternative splice variants were further validated by checking the mRNA expressions of seven peptide sequences with splice variations (Supplementary Table 8 ) by RT-PCR. The results were concordant with our proteomic analysis. All seven novel peptide coding sequences were amplified in both wild type and mutant samples (Figure 4a ). Amplified sequences ranged in size from 63 -75 bp (Figure 4a ). In addition,
we did the QT-PCR on four peptides which showed differential expression by TPP analysis (Figure 4b ). The expression profile for novel variants of pkm2 and pctk2 were similar to what we observed by TPP analysis. However, the expression profiles of novel variant of mdh1 and sol19a1 were opposite to what we observed from TPP analysis. We saw decreased mRNA expression of the novel mdh1 peptide in mutant sample versus the wild type. Even though the unique peptide for sol19a1 variant was identified by multiple spectra, the expression ratio was calculated by Q3Parser from a single spectrum.
Functional annotations of novel alternative splice variant proteins
Gene Ontology (GO) terms associated with the parent gene symbols of the novel splice variants of known proteins are given in Supplementary Table 4 . As expected, many proteins were extracellular. However, we observed splice variants of such nuclear proteins as high-mobility group box 2, DEAD box polypeptide 6, nuclear factor interleukin 3 regulated, and peptidylprolyl isomerase like 2. In the molecular function category, more splice variants were associated with metal ion binding and endopeptidase inhibitor activity. Under biological processes, many variants were involved in transport.
Supplementary Table 5 summarizes the list of genes with over-represented GO attributes using FuncAssociate.
Known alternative splice variant proteins
As mentioned earlier, 420 of the 1278 protein identifications were alternative splice variant proteins. By sequence analysis of the peptides identified from these 420 proteins, 92 were found as novel splice proteins. The peptides from the remaining 328 protein identifications matched to sequences from known mouse coding sequences. Variant proteins of many genes previously reported as involved in pancreatic cancer are in this list (Supplementary Table 6a ). In addition, variants of genes that were reported by other studies to be involved in other types of cancers are found in this set (Supplementary Table 6b ).
Relative expression analysis by Xpress and Q3Proteinparser produced expression ratios for 81 proteins out of 328 known splice variants (Supplementary Table 7 ). 48 of them had greater than two fold expression at 95% or more confidence interval in mutant samples relative to wild type. According to the analysis, the unique peptide that identified secreted and transmembrane 1A (sectm1a) showed the highest fold change in mutant samples. This protein was reported to have potential importance in hematopoietic and/or immune system processes (23).
Ten possible pancreatic cancer biomarkers were chosen by a parallel study on the same mouse model plasma samples (24) . Variants of three of these genes are found in our list of 420 splice variant proteins: lipocalin2 (lcn2), regenerating islet-derived 3 (reg3a) and TNF receptor superfamily, member 1A (tnfrsf1a). According to our expression analysis, tnfrsf1a showed > 2-fold change in expression in tumor samples compared to wild type.
Discussion
Alternative splicing allows a single gene to generate multiple mRNAs, which can be translated into functionally and structurally diverse proteins (25) . One gene can have multiple variants coexisting at different concentrations, so estimating the relative abundance of each variant may be important for the study of its biological role (25) . As Table 6 for citations, Supplementary Table 7 for expression ratios).
The focus of our work is on the novel variants, of which we annotate eight. First, we highlight three novel splice proteins with > 2-fold increase in mutant plasma compared to wild type which may have potential role in progression of pancreatic cancer: pyruvate kinase (pkm2), proteoglycan 4 (prg4) and malate dehydrogenase 1 (mdh1). The 95% confidence intervals for their > 2-fold expression ratios exclude unity. It would be interesting to investigate potential roles of these novel variants in pancreatic cancers.
A splice variant of high mobility group box 2 (hmgb2) showed > 2-fold increase in expression in mutant samples. Hmgb2 is involved in DNA repair. It has not been reported as upregulated in pancreatic cancer, but this gene is located at 4q32-34, a region identified as a potential locus for familial pancreatic cancer in a large American family (40) .
Another interesting protein is the novel splice variant of hepatocyte growth factor activator (hgfa), a serine protease that converts the inactive single-chain precursor of hepatocyte growth factor (hgf) to the active heterodimer in response to tissue injury (41) .
Results from Lee et al (42) suggest that extracellular receptor kinase activation by hgf might be important in pancreatic cancer metastasis.
We found many novel splice variants to glyceraldehyde-3-phosphate dehydrogenase (gapdh), another critical enzyme in glycolysis. Gapdh mRNA levels are over-expressed in many cancers; relative levels correlate with pathologic stage in prostate cancer (43) (44) (45) .
Chen et al (21) observed > 2-fold increase of gapdh in pancreatic cancer tissue using isotope-coded affinity tag (ICAT) technology followed by mass spectrometry.
The ECgene (http://genome.ewha.ac.kr/ECgene/) database uses the ECgene gene prediction algorithm to identify splice variants by EST clustering. Three levels of confidence (high, medium and low) were set on the gene models based on mRNA evidence (13) . The custom built ECgene database used for our study has another layer of complexity which is the 3-frame translation of ECgene sequences of predicted gene models, which makes it feasible to identify novel proteins. We found 8 proteins where no peptides matched to any known mouse protein sequences by blastp analysis (Supplementary Table 3 One focus in cancer biomarker discovery is driven by the approach that the most promising plasma biomarkers will be secreted proteins (46) . Gene Onotology analysis of the novel splice variants by FuncAssociate showed extracellular as a top-ranking attribute (Supplementary Table 5 ). Interestingly, the unique peptide with which we identified the novel protein M5C6460_1_s86_e1988_1_rf0_c1_n0| had a 71% sequence similarity to the peptide sequence of the extracellular protein, alpha fetoprotein, a 'gold-standard' in the field of tumor markers (47) . According to FuncAssociate analysis, endopeptidase inhibitor/endoproteinase inhibitor/proteinase inhibitor activity (GO: 0004866) is a topranking Gene Ontology attribute. Imbalanced protease activity has long been recognized in progression of cancers and inflammation (48) . Other high-ranking biological processes are glucose metabolism and lipid transport. There are many studies linking impaired glucose metabolism and pancreatic cancer (49, 50) . Supplementary Table 4 a) Threshold values applied were ProteinProphet probability value > 0.9 and X!Tandem expect value < 0.001.
b) The number in parentheses shows the false positive identifications that are from the reverse sequences.
c) To remove redundant proteins from the union of TPP and first phase MPPI analyses, a second round of MPPI was run on peptides found in both methods. 
